Evive Biopharmaceutical (Beijing) Ltd., a subsidiary held by Evive Biotech Ltd., possesses sophisticated pharmaceutical production facilities and a quality management system in compliance with the management specifications of NMPA, FDA and EMA, which ensure that commercial manufacturing can reach the highest standard in the industry.

Bioton is an innovative biotechnology company headquartered in Poland. Bioton is committed to providing safe and total treatment solutions for diabetics. As the second largest comprehensive pharmaceutical enterprise in Poland and the fourth listed recombinant human insulin manufacturer in the world, Bioton is the first and only company in Poland that can fully transform its technology into commercial use, thereby constantly promoting biotechnology development in Poland.
For more than two decades, Bioton has been providing daily support for diabetics around the world. Today, insulin products produced by Bioton are sold in more than 20 countries in Europe, South America, Asia and Africa. To meet different needs of its partners, the company provides finished insulin products and API, as well as technology transfer. Through technology development, education and scientific support for local communities, Bioton constantly improves the availability of insulin in other countries.

The manufacture scope of Hefei Yifan Biopharmaceutical covers: disinfectant products, sterile small volume injections (including anti-tumor products), sub-packaging of imported products (biologics for treatment), intraocular injection solutions, and oral solid preparations. The company has established a quality management system that meets the requirements of cGMP specifications such as NMPA, FDA and EMA, to ensure that the drugs it produces meet their intended purposes of use, and standards for marketing approval and clinical use. The company has world-class production equipment and sophisticated injection (including cytotoxic and highly active chemicals) production lines. Its laboratory management system complies with CNAS requirements, and its safety, environmental protection and occupational health management system complies with international ISO 14001 and OHSAS 18000 requirements. The company has established a modern intelligent monitoring system, such as BMS (Building Management System) and EMS (Online Environmental Monitoring System), so as to ensure that the online environmental monitoring of the production plant is effectively controlled, and the drug production is safe and sound.

Fisiopharma was founded in 1989 and is located in Italy. It is a company specializing in the production of sterile injections for solutions, suspensions and powder preparations. Fisiopharma is one of the "leading" companies engaged in the manufacture of high-tech generic drugs. It focuses on the R&D of new manufacturing technologies and new active pharmaceutical ingredient formula projects. Its sterile drugs approved for manufacture include highly active drugs, narcotic drugs and psychotropic substances.
Having its own facilities, Fisiopharma can cooperate in manufacture and act as an ideal partner for contracted manufacture to ensure maximum punctuality and efficiency. Fisiopharma is an ideal partner for the manufacture of generic drugs for injection and everything related to regulatory activities (batch validation, stability testing, process validation). In addition, Fisiopharma operates and sells its products in European market, which is the most important market, and non-European markets.

Suzhou Yifan Pharmaceutical is located in the north of Jinjiang Road, Suzhou Economic and Technological Development Zone, Anhui Province. The company has 12 API production lines and 10 API refining-drying-packing lines (final process of API manufacture), and can develop and produce polypeptides, anti-tumor drugs, hormones, contrast agents and other special APIs. The company has production lines for 17 dosage forms such as tablets, granules and capsules, and 21 preparations. It has 109 preparation approval numbers and 4 API varieties. The company now has five GMP certificates - production lines of tablets, hard capsules, powders, granules, mixtures (oral liquid), syrups, tinctures, pastes (including hormones) (including pre-treatment and extraction of TCMs); API urea production line; lotion production line; and API Ftibamzone production line.
The company has established a sound production quality management system, and has successively won the honorary titles of "City-level Leading Enterprise", "Honest Unit", "Pioneer in Scientific and Technological Innovation", etc. The company’s TCM extraction and multi-function micromolecular API (polypeptides, alkaloids, first-line anti-tumor drugs, etc.) synthesis project has been rated as a major emerging industry project in Anhui Province.

Liaoning Yifan Pharmaceutical is the manufacturing base of Yifan Pharmaceutical Group for chemical drugs and large volume injections. Its Solid Preparation Workshop has more than 50 manufacture approvals for solid preparations, including Amlodipine Besylate Tablets (consistency evaluation passed), Roxithromycin Tablets, Roxithromycin Capsules, and Ibuprofen for Suspension, with an annual output of 1 billion tablets, 300 million capsules, and 5 million bottles of suspensions. The Large Volume Injection Workshop of Liaoning Yifan has a glass bottle production line and a non-PVC soft bag production line, and its products include 100ml glass bottle Vinpocetine Sodium Chloride Injection, which is the only one in China, and 100ml glass bottle Ligustrazine Phosphate and Sodium Chloride Injection and 100ml glass bottle Gentamycin Sulfate and Sodium Chloride Injection, both of which are exclusive products in China, and have sold well domestically for years.
At present, the company has a sound quality management system and a mature pharmaceutical management team. The company adheres to its original aspiration of providing "safe and reliable drugs" for the public, keeps innovating and follows the trend of industry development. With the strong support of the parent company, the company has carried out R&D and project transfer of many new products, such as Nimodipine Injection, Tirofiban Injection, and Mecobalamin Tablets. Among them, the consistency evaluation research project of Amlodipine Besylate Tablets and the digital transformation project of the Large Volume Injection Workshop were approved as "Liaoning Innovation Achievement Transformation Project in 2021" and "Liaoning Intelligent Manufacturing Project", and were supported by government funds. In 2021, Liaoning Yifan was rated as "Young Eagle Enterprise" in Liaoning Province.

The product categories of the synthetic biological industrial park include human and animal nutrition products, raw materials, pharmaceutical preparation, medical and aesthetic products, and variety of vitamins products. The production technology is independently developed and improved by the company. Company has made great innovation in the continuous production process, equipment, and automatic controlling of manufacturing technique. The technology is more mature, the process is more advanced, and in line with the purpose of environmental protection. The project construction technology is also leading the market at home and abroad. Otherwise, the development of the project is playing a significant role in promoting the adjustment and optimization of the company’s product structure.

We, Hangzhou Xinfu Science &Technology Co.,Ltd., are the principle part of API business division 100% belong to our headquarter, Yifan Pharmaceutical Co.Ltd. which is a public limited group company (listed in Shenzhen Stock Exchange, stock code 002019).
Our production center, with the certificates of ISO9001/14001/22000/45001, Kosher, Halal, BRC, CEP, Fami-Qs, etc. started the R&D, production, global sales and service on the business of D-Calcium Pantothenate and Panthenol series products in Lin’an Distr., Hangzhou, China, since 1995. After more than 27 years of stable development, we have been the global-leading brand name, the most reliable producer and supplier with our regular business partners in worldwide market on the basis of our remarkable advantages, such as, global-leading production technology, own know-how and patents, professional terms on R&D/production/QC/Sales & service, experienced management teams, strong capability of financial operating system under the background of public limited corporation system.
Since 2018, we have started a lots R&D projects co-operation with Amyris, which is listed on NASDAQ, one of the top leading R&D technical companies on Synthetic Biology. Several of these projects has achieved an outstanding progress, and been ready for commercial process. We also has set up deep, extensive, and fruitful co-operation relationship with Bota Bio, Cataya Bio, etc. high-tech Synthetic Biology companies in China. We have set up and been operating series high-tech R&D platforms, such as Academician Workstation, National post-doctoral research station, Provincial Key Enterprise Research Institute, etc. We also set up industry-university- research cooperation with Lanzhou University, Jiangnan University, Zhejiang University of Technology, etc. In conclusion, to meet the future, we have been concentrating on more valued new projects of technical preparation and strategic layout on in order to match the market demanding and challenging.
We confidently hope to develop new co-operation relationship and to win together with more reliable new business partners on the basis of mutual trust and sustainable benefits!

Chongqing Xinfu Chemical is a national high-tech company, with an annual 6,000 tons output of D-Panthenol ide, and carrying out ISO9001 Quality Management System, ISO14001 Environmental Management System, OHASA18001 Occupational Health and Safety Management System, meet the standard evaluation requirements through implementing the safety production standardization and production management ability is geared to international standards gradually.
We keep focusing on company’s scientific and technological innovation, and take independent innovation as the core competitiveness, increasing investment in technological upgrade and revolution. We consider maintaining the advantages of Pantothenic Acid series products, and vigorously develop the high-tech environmental protection industry, expand in the fine chemical industry steadily, and duly launch the project of natural gas industrial chain with its extensional projects. In order to format the pantothenic acid series, HCN and its derivatives as superior products, strengthen the management ability.
The company adheres the far-sighted, strategic concept of “Green Chemical Industry”, we have introduced newer and cleaner production technology to achieve the purpose of environmental protection. Chongqing Xinfu promises to establish a resource-saving, environmentally friendly, and safe company. Thus, we have increased our investment in safety and environmental protection year by year, which has exceeded 40 million RMB so far. We have profoundly realized the significance of environmental safety and have implemented effective precautions and management methods to solve “The Three Wastes” problem properly.

Anqing Xinfu Chemical's main products are β-Alanine with annual output of 6000 tons, high-purity β-alanine with 2,500 tons, and 1,500 tons of 3-aminopropanol and hydroxy propionitrile. We rely on scientific and technological improvement and study from international standards to promote our standardization task. Our company has successively established and implemented ISO9001 Quality Management System, GB/T24001 Environmental Management System, GB/T28001 Occupational Health and Safety Management System, GB/T22000 Food Safety Management System, European BRC Food Safety Management System and has passed FAMI-QS, HALAL, KOSHI certification test.
Anqing Xinfu is a national high-tech, provincial specialized company. We have provincial and municipal digital workstation, with a municipal technology center. And we innovate and develop our main products independently, in line with the national industrial guidance. Our technical skills are leading the domestic market, the quality of our products is acting on international convention.

Sichuan Defeng Pharmaceutical is a national high-tech enterprise mainly engaged in drug R&D and production, and its products are mainly drugs for dermatological, gynecological, pediatric, orthopedic, cardio cerebrovascular diseases. The company produces 15 dosage forms, including granules, ointments, capsules and sprays, all of which have passed the GMP compliance on-site inspection. At present, the company has 82 drug registration certificates, including 15 national exclusive varieties (dosage forms). Its eight leading products including Dehumidifying and Antipruritic Ointment, Skin Allergy Relieving Capsules, Emedastine Difumarate Sustained-release Capsules and Oxytocin Nasal Spray have entered the new version of National Medical Insurance Reimbursement List, and Dehumidifying and Antipruritic Ointment has entered the National Essential Drugs List. The company has always adhered to the strategy of scientific innovation orientation. Relying on the strong technical background and powerful R&D team of Yifan Pharmaceutical, the company has gained approval for establishment of a provincial-level enterprise technology center, a city-level engineering technology center and other innovative R&D platforms. The company has been constantly increasing its R&D investment, which has generated remarkable R&D efficiency and outcomes. At present, the company has 33 domestic authorized patents, including 11 invention patents, 22 utility model patents and 1 international PCT patent.

Tianchang Yifan Pharmaceutical is a high-tech enterprise specializing in the production of Chinese patent medicines for more than two decades, with an annual production capacity of about 15 million boxes in 43 varieties.
Adopting a high starting point approach for its factory construction, the company introduced domestically leading drug production and testing equipment, and became the first drug manufacturer in Anhui Province that fully passed the national GMP acceptance check on March 21, 2000. At present, the company has multiple production lines for granules, tablets, capsules, mixtures (oral liquid), guttate pills, etc. Starting with common diseases and frequently occurring diseases, the New Drug R&D Department of the company has successively launched new products, and constantly developed its own flagship products: Compound Realgar Natural Indigo Tablets, a special drug for treating acute promyelocytic leukemia. A researcher of the company Professor Huang Shilin received an order of commendation from President Jiang Zemin on June 27, 2002, and won the second prize of the National Science and Technology Progress Award in November 2011. In addition, Compound Yinhua Detoxicating Granules of the company, a national second-class protected TCM variety, has been accredited as a National Innovation Fund Project; and its Maqin Cough-relieving Granules for acute and chronic tracheitis, Yandan Capsules for cardiovascular and cerebrovascular diseases, and Hawthorn Essence Lipid Lowering Dropping Pills for hyperlipidemia, have been accredited as exclusive national Class III new drugs. Apart from the new special-effect drugs above, the company also produces a large number of products having huge market potential and unique curative effect, such as Stasis-dissolving and Freckle Removing Capsules, which is a beauty product having code number approved by NMPA, as well as Fuyan Kangfu Granules for obstetrical and gynecological diseases, and Xinshenghua Granules. In addition, the company has more than 20 provincial bid-winning varieties, drugs on the National Medical Insurance Reimbursement List, and those on the National Essential Drugs List, such as Ganmaoling Granules, Weishuning Granules, Huanglian Shangqing Tablets, Yangxue Anshen Tablets, Yuanhu Pain-relieving Capsules, which belong to general drugs. The product line structure of the company is being constantly enriched.